All In Biotech

Drug Trial Radar · NCT07594769

A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults

A PHASE 1, OPEN LABEL, SINGLE DOSE, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF TWO FORMULATIONS OF A CGRP RECEPTOR ANTAGONIST IN HEALTHY ADULT PARTICIPANTS

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

May 11, 2026

Primary completion

Sep 1, 2026

Study completion Sep 1, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the bioequivalence of an alternative ODT formulation (ODT2) versus the approved ODT formulation of a CGRP receptor antagonist in healthy adult participants under fasting conditions.

Conditions

  • Migraine

Interventions

  • ODT2 Test formulationDrug

    Test Formulation

  • ODT Reference formulationDrug

    Reference Formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of the test and reference formulationsTime frame: Pre-dose to 72 hours
  2. Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast) of the test and reference formulationsTime frame: Pre-dose to 72 hours
  3. Maximum observed plasma concentration (Cmax) of test and reference formulationsTime frame: Pre-dose to 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer Clinical Research Unit - Brussels

    Brussels, Bruxelles-capitale, Région de, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.